|Mr. David Fellows||CEO & Director||N/A||N/A||1957|
|Mr. Senthil Sundaram||CFO & Principal Accounting Officer||N/A||N/A||1978|
|Dr. Gregory Robinson Ph.D.||Chief Scientific Officer||N/A||N/A||1959|
|Mr. Aniz Girach||Chief Medical Officer||N/A||N/A||N/A|
|Dr. Tuyen Ong M.D., MRCOphth, MBA||Exec. VP & Chief Devel. Officer||N/A||N/A||1975|
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. The company was founded in 2013 and is headquartered in London, the United Kingdom.
Nightstar Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.